Patient Advocate Foundation Receives Support to Aid Lung Cancer Survivors through Its Co-Pay Relief Program
The Patient Advocate Foundation has received a generous contribution that will allow the Foundation to continue to support people with non-squamous non-small cell lung cancer within its Co-Pay Relief Program. The program provides direct financial support for pharmaceutical co-payments to insured patients, including Medicare Part D beneficiaries, who financially and medically qualify, significantly reducing the financial burden associated with high medication costs.
- Patient should be insured and insurance must cover the medication for which patient seeks assistance.
- Patient must have a verified diagnosis of Non-Small Cell Lung Cancer
- Patient must reside and receive treatment in the United States.
- Patient's income must fall below 500% of the Federal Poverty Level.
Information About the Disease
About 85% to 90% of lung cancers are non-small cell lung cancer (NSCLC). There are 3 main subtypes of NSCLC. The cells in these subtypes differ in size, shape, and chemical make-up when looked at under a microscope. But they are grouped together because the approach to treatment and prognosis (outlook) are very similar.
Squamous cell (epidermoid) carcinoma: About 25% to 30% of all lung cancers are squamous cell carcinomas. These cancers start in early versions of squamous cells, which are flat cells that line the inside of the airways in the lungs. They are often linked to a history of smoking and tend to be found in the middle of the lungs, near a bronchus.
Adenocarcinoma: About 40% of lung cancers are adenocarcinomas. These cancers start in early versions of the cells that would normally secrete substances such as mucus. This type of lung cancer occurs mainly in people who smoke (or have smoked), but it is also the most common type of lung cancer seen in non-smokers. It is more common in women than in men, and it is more likely to occur in younger people than other types of lung cancer. Adenocarcinoma is usually found in the outer region of the lung. It tends to grow slower than other types of lung cancer, and is more likely to be found before it has spread outside of the lung. People with the type of adenocarcinoma called adenocarcinoma in situ (previously called bronchioloalveolar carcinoma) tend to have a better outlook (prognosis) than those with other types of lung cancer.
Large cell (undifferentiated) carcinoma: This type of cancer accounts for about 10% to 15% of lung cancers. It may appear in any part of the lung. It tends to grow and spread quickly, which can make it harder to treat. A subtype of large cell carcinoma, known as large cell neuroendocrine carcinoma, is a fast-growing cancer that is very similar to small cell lung cancer.
Other subtypes: There are also a few other subtypes of non-small cell lung cancer, such as adenosquamous carcinoma and sarcomatoid carcinoma. These are much less common.
♦ ♦ ♦ ♦ ♦
For more information or to apply, visit copays.org or call (866) 512-3861.
This article was originally published in Coping® with Cancer magazine, September/October 2012.